MEDP

T3S&P 1500Growth (IWF)

Medpace Holdings, Inc.

Next est. report · AMC

Loading…
Loading chart…
Overview

Medpace Holdings, Inc. is a contract research organization (CRO) providing comprehensive clinical development services, from early-stage trials to post-market s

Medpace Holdings, Inc. is a contract research organization (CRO) providing comprehensive clinical development services, from early-stage trials to post-market support. They assist pharmaceutical, biotechnology, and medical device clients, primarily smaller companies, across North America, Europe, and Asia. While metabolic work previously drove growth, oncology now represents over half of new bookings and awards. Their top 10 customers account for approximately 39% of revenue.

Key Inputs And Sourcing

1. Labor (Salaries, Wages, Benefits)

Not in registry

labor · Global · unknown

Source Medpace expanded its global workforce to approximately 6,500 employees across 46 countries as of June 30, 2026. The earnings transcript discusses headcount growth and pressures on salaries, wages, and benefits.

Confidence: high

2. Reimbursable Costs / Pass-Through Expenses

Not in registry

other · Global · 40-42% of revenue

Source These are direct costs passed to the sponsor at actual cost, including site and PI grant fees, external vendor costs, travel, and insurance. Kevin Brady stated the reimbursable component of direct costs is expected to be 41-42% of revenue for Q3 and Q4 2026.

Confidence: high

3. Clinical Site & Investigator Fees (Grants)

Not in registry

other · Global · unknown

Source These are a significant part of pass-through costs, paid to principal investigators and sites for patient recruitment and trial execution.

Confidence: high

4. Subcontracted Services / External Vendors

Not in registry

other · Global · unknown

Source Includes costs for central labs, independent data monitoring committees (IDMC), ePRO (electronic patient-reported outcomes) providers, and other specialized services. These are part of pass-through costs.

Confidence: medium

5. Data Management & Technology (Software/Licenses)

Not in registry

component · Global · unknown

Source Costs for electronic data capture (EDC) system licenses, data cleaning, statistical programming, and investments in AI platforms are significant.

Confidence: medium

6. Facilities / Real Estate

Not in registry

other · North America (primarily US) · unknown

Source Medpace is undertaking a significant expansion in Cincinnati, adding approximately $20 million in operating costs in 2027.

Confidence: medium

7. Travel & Logistics

Not in registry

logistics · Global · unknown

Source Costs associated with clinical monitors traveling to sites and other logistical expenses are often billed as pass-throughs.

Confidence: medium

8. Regulatory Fees & Insurance

Not in registry

other · Global · unknown

Source Fees for regulatory submissions (e.g., IND, IDE), safety reporting, audits, and patient insurance are critical costs.

Confidence: medium

Industry Publications

  • FierceBiotech (fiercebiotech.com) — Provides daily news on biotechnology innovation, funding, drug approvals, and emerging technologies, including AI-driven drug discovery, which directly impacts Medpace's client base and service offerings. Also covers CRO industry trends and challenges. [cite: 1, 2, 17, 28, Theme_Overview]
  • Endpoints News (endpts.com) — Offers in-depth reporting and analysis on the biotechnology and pharmaceutical industries, with strong coverage of financing, deals, and strategic shifts, including those impacting CROs and AI in biopharma. [cite: 14, 15, 20, 25, Theme_Overview]
  • Clinical Leader (clinicalleader.com) — Highly relevant for monitoring Medpace's core business, as it focuses on clinical research, trial execution, oversight, and operational challenges within the CRO industry.
  • Scrip (pharmaintelligence.informa.com/products/scrip) — Provides global pharmaceutical and biotech news, analysis, and data, including regulatory developments and market trends relevant to CROs. It has also recognized top CROs with awards.
  • Life Sciences Review (lifesciencesreview.com) — Features listings of 'Top Contract Research Organizations (CROs)' and covers topics like clinical trials, drug discovery, and biotech, offering insights into Medpace's competitive landscape and industry standing.

Economic Data Watch

1. Federal Reserve Board — H.15 Selected Interest Rates

Not in registry

Metric/field Federal Funds Effective Rate (DFF)

Cadence monthly

Why it matters Influences the cost of capital for growth-oriented biotechnology companies and impacts investor risk appetite for early-stage assets.

Signal to watch Decreasing rate is bullish, increasing rate is bearish.

Confidence: high

2. BEA — National Income and Product Accounts

Not in registryaccess=api

Metric/field Real Gross Domestic Product (A191RL1Q225SBEA)

Cadence quarterly

Why it matters Overall economic growth impacts corporate profitability and R&D budgets across the pharmaceutical and biotech industries.

Signal to watch Increasing growth is bullish, decreasing growth is bearish.

Confidence: high

3. Federal Reserve Board — Industrial Production and Capacity Utilization

Not in registry

Metric/field Industrial Production: Pharmaceuticals and Medicines (NAICS 3254) (IPG3254N)

Cadence monthly

Why it matters Directly reflects production activity in the pharmaceutical sector, indicating demand and investment in drug manufacturing, which can correlate with clinical trial activity.

Signal to watch Increasing production is bullish, decreasing production is bearish.

Confidence: high

4. BLS — Consumer Price Index

Not in registryaccess=api

Metric/field Consumer Price Index for All Urban Consumers: All Items in U.S. City Average (CPIAUCSL)

Cadence monthly

Why it matters High inflation can increase operating costs for CROs and impact overall economic stability, potentially affecting R&D budgets.

Signal to watch Stable or decreasing inflation is bullish, increasing inflation is bearish.

Confidence: high

5. Trading Economics — China Industrial Production

Not in registryaccess=scrape

Metric/field China Industrial Production

Cadence monthly

Why it matters China is a significant market for pharmaceutical R&D and manufacturing. Its industrial health can indicate broader economic trends affecting global biotech investment and activity.

Signal to watch Increasing production is bullish, decreasing production is bearish.

Confidence: high

Free Alt Data Watch

1. ClinicalTrials.gov — Study Records

Not in registry

Metric/field Number of new studies registered with 'Biotechnology' or 'Pharmaceutical' as lead sponsor

Cadence daily

Why it matters Directly indicates the pipeline of new clinical trials, which is the core business for CROs like Medpace.

Signal to watch Increasing new registrations is bullish, decreasing is bearish.

Confidence: high

2. SEC EDGAR — 8-K Filings

Not in registry

Metric/field Number of 8-K filings by biotech/pharma companies related to funding, M&A, or clinical trial results

Cadence daily

Why it matters Provides real-time insights into significant events affecting Medpace's client base, such as funding rounds or M&A, which can impact project continuity or new business.

Signal to watch Increased positive funding/trial news is bullish, increased negative news or M&A (for Medpace's clients) is bearish.

Confidence: medium

3. Google Trends — Search Interest Data

Not in registry

Metric/field Search interest for 'AI drug discovery' (worldwide)

Cadence weekly

Why it matters Indicates public and industry interest in the core technology driving the theme, signaling broader awareness and potential adoption.

Signal to watch Increasing search interest is bullish, decreasing is bearish.

Confidence: high

4. Medpace Holdings, Inc. Investor Relations — Press Releases

Not in registry

Metric/field Number and content of press releases related to new business awards, partnerships, or operational updates

Cadence irregular

Why it matters Direct announcements from the company provide immediate insight into business momentum, new client wins, and strategic developments.

Signal to watch Positive announcements (new awards, strong partnerships) are bullish, lack of updates or negative news is bearish.

Confidence: high

5. USPTO PatentsView — Patent Grants

Not in registry

Metric/field Number of patent grants in biotechnology and pharmaceutical fields by assignee (small/mid-cap companies)

Cadence monthly

Why it matters Indicates innovation and R&D output within the biotech and pharmaceutical industries, which drives future clinical trial demand.

Signal to watch Increasing patent activity from Medpace's target client base is bullish, decreasing activity is bearish.

Confidence: medium

Paid Alt Data Watch

1. Revelio Labs — Jobs / Workforce Data

Not in registryaccess=file

Metric/field Total job postings for 'Clinical Research Associate' OR 'Clinical Project Manager' within CRO industry

Cadence monthly

Why it matters Hiring trends for key roles in CROs indicate industry capacity expansion and demand for clinical trial services.

Signal to watch Increasing job postings are bullish, decreasing are bearish.

Confidence: high

2. Norstella / GlobalData Healthcare / Clarivate Life Sciences & Healthcare — Healthcare Claims / Rx Data

Matchednorstella_clinical_trials_catalysts · access=file · map_only

Metric/field Number of active clinical trials by therapeutic area (Oncology, Metabolic) and phase

Cadence monthly

Why it matters Provides granular insight into the therapeutic mix and phase distribution of ongoing clinical trials, directly impacting Medpace's project pipeline and specialization.

Signal to watch Increasing trials in Medpace's focus areas (e.g., Oncology) is bullish, decreasing is bearish.

Confidence: high

3. PitchBook / Crunchbase / CB Insights — Venture Capital Funding Data

Not in registry

Metric/field Total venture capital funding rounds and dollar value for small/mid-cap biotechnology companies

Cadence quarterly

Why it matters Directly tracks the funding environment for Medpace's primary client base, indicating their capacity to initiate and fund new clinical trials.

Signal to watch Increasing funding is bullish, decreasing is bearish.

Confidence: high

4. Similarweb / Datos — Web Traffic Data

Matchedsimilarweb_website_traffic_engagement · access=file · map_only

Metric/field Website traffic to Medpace's corporate and investor relations pages

Cadence monthly

Why it matters Indicates investor and industry interest in Medpace, potentially correlating with business development activity or market sentiment.

Signal to watch Increasing traffic (especially to IR pages) is bullish, decreasing is bearish.

Confidence: medium

5. IQVIA — R&D Spend Forecasts

Not in registry

Metric/field Global Biopharmaceutical R&D spending forecasts and actuals

Cadence quarterly

Why it matters Provides a macro view of the overall R&D investment by the biopharmaceutical industry, which drives demand for CRO services.

Signal to watch Increasing R&D spend is bullish, decreasing is bearish.

Confidence: high

Search Keywords Brand Product

  • contract research organization
  • CRO services
  • clinical development
  • clinical trials
  • drug discovery
  • biotechnology research
  • pharmaceutical research
  • medical device trials
  • oncology trials
  • metabolic disease research
  • Phase I-IV clinical trials
  • bioanalytical laboratory services
  • ECG core laboratory
  • imaging services

Search Keywords Event Phrases

  • Medpace earnings
  • Medpace Q3 2026 results
  • AI drug discovery summit
  • biotech AI partnerships

Search Keywords Policy Regulatory

  • FDA AI drug development guidance
  • EMA AI in pharma regulation
  • AI clinical trial guidelines
What They Do (Plain English & Analogies)
Medpace acts like a specialized, outsourced research and development department for companies that are creating new medicines, medical devices, or other health treatments. Instead of these pharmaceutical, biotechnology, and medical device companies doing all the complex and time-consuming testing themselves, they hire Medpace. Medpace handles the entire process of clinical trials, from the very first tests in humans (Phase I) all the way through to post-market support (Phase IV). This includes designing the studies, managing patient data, ensuring everything follows strict government rules, running the trials, analyzing the results, and providing specialized lab testing like bio-analytical, ECG, and imaging services. Essentially, they help bring new treatments to market faster and more efficiently by providing a comprehensive, integrated platform for clinical research. Think of them as a highly specialized general contractor for drug and device development, managing all the intricate steps from blueprint to final approval.
Very Brief History
Medpace Holdings, Inc. was founded in Cincinnati, Ohio, in 1992 as Medical Research Services. Over the years, it has evolved into a global contract research organization (CRO) providing a comprehensive suite of clinical development and research services across various therapeutic areas. The company started trading stock as a public firm in 2016.
"Street Stereotype"
The 'Street stereotype' for Medpace often involves scrutiny over its valuation, with investors perceiving it as having a premium multiple. This perception is amplified by recent concerns about slowing sequential growth and a declining backlog coverage beyond the next 12 months. The market is particularly focused on whether Medpace's growth trajectory can justify its valuation, especially given the recent negative reaction to booking trends and future growth prospects.
Subsidiaries On Linked In*
{"subsidiaries":[]}
Customer Sectors & Example Clients
Medpace's customers are primarily in the pharmaceutical, biotechnology, and medical device industries. They specifically focus on serving virtual and smaller companies, rather than large pharmaceutical firms. While specific client names are not disclosed due to confidentiality, their customer base consists of numerous small to mid-sized biotech and pharma firms developing new therapies and devices.
New Customers / Segments They'Re Targeting
Medpace is not explicitly targeting entirely new customer types or segments beyond its existing focus on pharmaceutical, biotechnology, and medical device clients. Instead, the company is focused on improving its win rate within its existing client base and adapting to shifts in therapeutic demand, such as the current pivot back towards oncology from metabolic work.
Sales Geographies And Expansion Plans
Medpace currently sells its services geographically across North America, Europe, and Asia. The company also has a presence in Latin America and South Africa. Management has not indicated specific plans to expand sales into new geographies, but rather focuses on expanding its pipeline and improving its win rate within its existing global footprint. Operationally, Medpace is bringing a significant expansion online in Cincinnati, which will add about $20 million in operating costs in 2027.
How Key Themes May Help/Hurt
The 'Biotech '26: AI Driven Drug Discovery' theme presents both opportunities and challenges for Medpace. The company expects to invest significantly in AI over the next two years, anticipating net benefits in efficiency only a few years down the line. This substantial upfront capital investment could create a drag on near-term profitability and operational efficiency before long-term gains are realized. However, the widespread integration of AI tools across the biotech value chain, from target identification to clinical trial optimization, could ultimately enhance Medpace's service offerings, streamline its operations, and improve data quality and trial efficiency, aligning with the broader industry trend of accelerating drug development timelines and costs.

3 Main Long-Term Bull Details

  1. Specialized Full-Service Model: Medpace's comprehensive, internally-driven, full-service model for clinical development is highly valued by smaller and virtual biotech companies, allowing them to outsource complex R&D efficiently and providing a single, accountable partner for clinical research, data, labs, and regulatory support.
  2. Strong Financial Performance & Cash Generation: The company has demonstrated robust financial performance, with significant revenue and EBITDA growth, strong cash flow from operating activities, and a healthy cash balance, indicating operational efficiency and financial stability.
  3. High-Quality Opportunity Flow & Improving Business Environment: Medpace is experiencing a strong business environment with record net bookings, reduced cancellations, and increasing RFPs of good quality, suggesting sustained demand for its specialized services and a healthy pipeline for future growth.

3 Main Long-Term Bear Details

  1. Backlog Volatility and Conversion Rate: While the third quarter of 2026 saw strong net new business awards, concerns about the long-term backlog coverage persist. The backlog conversion rate, while currently at 23.8%, is influenced by policy implementations regarding decision points in trials, and its future trajectory is uncertain, potentially impacting future revenue visibility.
  2. Exposure to Biotech Funding Volatility and M&A Impact: Medpace's client base, primarily smaller and virtual biotechs, is inherently sensitive to fluctuations in capital markets and biotech funding. Additionally, client acquisitions by larger pharmaceutical companies can be detrimental, as acquired clients may cut Medpace out of future work, creating ongoing competitive pressure.
  3. Initial AI Investment Outweighs Near-Term Benefits: Management expects to invest significantly in AI over the next two years, with the anticipation of net benefits in efficiency only a few years down the line. This substantial upfront capital investment could create a drag on near-term profitability and operational efficiency before long-term gains are realized.
Competitors And Differentiation
Medpace's competitors include large, full-service CROs such as IQVIA, ICON plc, Labcorp (Drug Development/Fortrea), Charles River Laboratories, Parexel, PPD (part of Thermo Fisher Scientific), and Syneos Health. Medpace differentiates itself through its scientifically-driven, global, full-service CRO model, particularly serving smaller to mid-sized biotech companies. They emphasize their integrated services, medical and regulatory expertise, and a collaborative model. The company also highlights its organic growth model and aims for close, individual relationships with its partners, focusing on the quality of its deliverables rather than aggressive pricing.
Recent Performance & What The Market'S Focused On
Medpace reported a strong third quarter of 2026, with revenue of $716 million, an 8.5% year-over-year increase. Net income increased 23.7% to $137.5 million, or $4.84 per diluted share. EBITDA grew 16% to $172.1 million, with an EBITDA margin of 24%. Net new business awards reached an all-time high of $873 million, a 10.6% increase year-over-year, and the last 12-month closing awards increased 23.9%. Ending backlog as of September 30, 2026, was approximately $3.2 billion, up 5.6% from the prior year. The company updated its full-year 2026 guidance, expecting total revenue in the range of $2.835 billion to $2.855 billion, and diluted EPS in the range of $17.97 to $18.32. For 2027, management indicated that current analyst consensus estimates appear reasonable. The market is focused on the strong bookings performance, the sustainability of the improved win rate, the impact of cancellations (which were higher than desired in Q3 but manageable), and the evolving therapeutic mix with a return to oncology.
Revenue Segments And Estimated Mix
  • Oncology — Mix: Large area, increasing in new awards and opportunities; Source: Q3 2026 earnings transcript; Trend: Pivoting back towards traditional oncology, with strong pending opportunities.
  • Cardiometabolic (including GLP-1 related work) — Mix: Significant segment, but less demand at current time point for new awards, though pending opportunities are strong; Source: Q3 2026 earnings transcript; Trend: Less metabolic demand at current time point in terms of awards, but a lot of pending opportunities for metabolic work.
  • Other Therapeutic Areas — Mix: n/m; Source: Q3 2026 earnings transcript; Trend: Cancellations in Q1 2026 were noted in oncology and cardiovascular, considered usual.
Product Brands
{"brands":[]}
Bull / Bear Details

Medpace Holdings, Inc. demonstrates sustained momentum as of October 23, 2026, driven by record Q3 net bookings, strong LTM awards, and an upgraded 2026 outlook

Thesis

Medpace Holdings, Inc. demonstrates sustained momentum as of October 23, 2026, driven by record Q3 net bookings, strong LTM awards, and an upgraded 2026 outlook. Operational execution and a new $1 billion share repurchase authorization underpin a bullish case. While cancellation unpredictability and lower implied 2027 growth require monitoring, the robust business environment and strategic adjustments mitigate concerns, positioning MEDP favorably.

Bull case

  • Medpace achieved an all-time high in net new business awards in Q3 2026, increasing 10.6% year-over-year to $873 million, with last 12-month closing awards up 23.9%. Management anticipates another record quarter for awards in Q4, signaling robust future revenue potential and continued strong demand for its specialized CRO services.

  • The company upgraded its full-year 2026 guidance across revenue, EBITDA, net income, and EPS, reflecting increased confidence in operational execution and strong Q3 EBITDA margins (24%). Furthermore, the board approved a new $1 billion share repurchase authorization, effective October 20, 2026, demonstrating commitment to shareholder returns and financial strength.

  • Medpace continues to benefit from a strong business environment, characterized by high-quality RFP activity and an improved win rate following strategic adjustments in late 2025. The therapeutic mix is favorably shifting back towards traditional oncology, with promising pending metabolic opportunities, ensuring a diversified and healthy pipeline.

Bear case

  • Despite strong bookings, the unpredictability of backlog cancellations remains a significant risk. Q3 cancellations were "toward the higher end" of the expected range, and management explicitly states that future cancellations are "beyond my ability to even predict," posing a threat to net bookings and future revenue visibility.

  • The implied growth rates for 2027 are "definitely lower than what Medpace usually does," and the new Cincinnati campus expansion will add approximately $20 million in operating costs in 2027. This, coupled with potential normalization of the backlog conversion rate, could decelerate revenue recognition and impact future growth trajectory.

  • Medpace continues to exhibit notable customer concentration, with its top 5 and top 10 clients accounting for approximately 31% and 39% of its last 12 months' revenue, respectively. The ongoing risk of client acquisitions by larger pharmaceutical companies, which often result in Medpace being cut out of future work, introduces client-specific execution and funding risks.

Bull / Bear Case
Bear Case
Despite strong bookings, the unpredictability of backlog cancellations remains a significant risk, with Q3 cancellations being "toward the higher end" of the expected range. Management explicitly states that future cancellations are "beyond my ability to even predict," posing a threat to net bookings and future revenue visibility. The implied growth rates for 2027 are "definitely lower than what Medpace usually does," and a new Cincinnati campus expansion will add approximately $20 million in operating costs in 2027. This, coupled with potential normalization of the backlog conversion rate, could decelerate revenue recognition and impact future growth trajectory. Medpace also exhibits notable customer concentration, with its top 5 and top 10 clients accounting for approximately 31% and 39% of its last 12 months' revenue, respectively, introducing client-specific execution and funding risks.
Bull Case
Medpace achieved an all-time high in net new business awards in Q3 2026, increasing 10.6% year-over-year to $873 million, with last 12-month closing awards up 23.9%. Management anticipates another record quarter for awards in Q4, signaling robust future revenue potential and continued strong demand for its specialized CRO services. The company upgraded its full-year 2026 guidance across revenue, EBITDA, net income, and EPS, reflecting increased confidence in operational execution and strong Q3 EBITDA margins (24%). Furthermore, the board approved a new $1 billion share repurchase authorization, demonstrating commitment to shareholder returns and financial strength. Medpace continues to benefit from a strong business environment, characterized by high-quality RFP activity and an improved win rate following strategic adjustments, ensuring a diversified and healthy pipeline.
More Compelling & Why
Bear. Medpace's current P/E ratio of approximately 36x-37x is significantly above the broader healthcare sector average of 18x-25x and its own 10-year median. Despite strong Q3 2026 bookings, management explicitly indicated "definitely lower" implied growth rates for 2027 and highlighted the unpredictability of backlog cancellations, which were at the higher end in Q3. This, coupled with an anticipated $20 million in new operating costs for 2027, suggests a deceleration in future profitability that is not justified by its current premium valuation. A material de-rating of the stock's P/E multiple to align with lower growth expectations, or a significant and sustained improvement in backlog cancellation predictability coupled with a clear path to re-accelerated growth in the forthcoming 2027 guidance, would flip my view.
Key Factors5 rows
Key FactorWhy It MattersWhat To WatchWhat It SignalsWhere/How To TrackFree Alt DataPaid Alt Data
Therapeutic Mix Shift and Metabolic OpportunitiesThe shift in new awards towards oncology and away from metabolic impacts the stability and growth profile of the backlog. However, the presence of many pending metabolic opportunities could rebalance the mix.Management commentary on the mix of new business awards and RFP activity, specifically noting the balance between oncology and metabolic work. Look for updates on the conversion of "pending opportunities for metabolic" into awards.Bullish if the metabolic opportunities convert into new awards, diversifying the backlog and reducing reliance on a single therapeutic area, while oncology remains strong. Bearish if metabolic awards continue to decline, increasing concentration risk or signaling a sustained slowdown in that segment.Company earnings conference call transcripts and investor presentations (Q4 2026 earnings call in February 2027).

[]

[]

2027 Full-Year Financial GuidanceThe official revenue and EBITDA guidance for 2027 will provide critical forward-looking insight into management's expectations, directly influencing analyst models and investor sentiment for future growth.The specific revenue and EBITDA ranges provided for 2027. Compare these figures to current analyst consensus estimates. Management currently sees "no large disconnect".Bullish if the 2027 guidance is in line with or above current analyst consensus estimates, or if management expresses increased confidence in the growth trajectory. Bearish if guidance is significantly below consensus or indicates a deceleration in growth.Company earnings press release and conference call transcript for Q4 2026 earnings (expected in February 2027).

[]

[]

Utilization of $1 Billion Share Repurchase AuthorizationThe new $1 billion share repurchase authorization signals management's confidence in the company's valuation and commitment to returning capital to shareholders, which can support the stock price.Any announcements regarding actual share repurchases made under the new $1 billion authorization, effective October 20, 2026.Bullish if the company actively utilizes the authorization to repurchase a significant amount of shares, demonstrating confidence and providing shareholder value. Bearish if there is no or minimal utilization, potentially signaling a lack of confidence or alternative capital allocation priorities.Company press releases, SEC filings (e.g., 10-Q, 10-K), and earnings call commentary (Q4 2026 earnings call in February 2027).

[]

[]

Quarterly Backlog Cancellation RateCancellations directly erode future revenue visibility and backlog stability. Management emphasizes that the cancellation profile in Q4 is a "large part" of shaping 2027 revenue expectations, calling them a "wild card".Management commentary on the backlog cancellation rate in Q4 2026. Specifically, whether the rate remains "within the kind of range we would expect" or increases significantly.Bullish if the cancellation rate remains stable or decreases from Q3 2026 levels (described as "toward the higher end, but within the kind of range we would expect"). Bearish if the rate increases significantly, indicating unexpected project terminations.Company earnings press releases and conference call transcripts (Q4 2026 earnings call in February 2027).

[]

[]

Net New Business Awards (Net Bookings) GrowthThis metric directly indicates Medpace's ability to secure new contracts and future revenue potential, validating strong market demand for its services and supporting the bullish growth thesis. Sustained high awards are crucial for backlog expansion.The absolute dollar value of net new business awards and its year-over-year growth rate in Q4 2026 and subsequent quarters. Management expects Q4 to be "another record awards".Bullish if net new business awards continue to show strong year-over-year growth (e.g., sustaining or exceeding the last 12-month growth of 23.9%) and reach new record highs. Bearish if growth decelerates significantly or turns negative.Company earnings press releases and conference call transcripts (Q4 2026 earnings call in February 2027).

[]

[]

Key Reported Metrics, Reratings Triggers & Results3 rows

Total Revenue is a primary indicator of operational performance and market demand. Investors will closely watch if Medpace can sustain its growth trajectory, es

Upcoming print · 2027-02-08

Key reported metrics
MetricLast periodWhy it matters
Total Revenue$716 million (8.5% y/y growth)

Total Revenue is a primary indicator of operational performance and market demand. Investors will closely watch if Medpace can sustain its growth trajectory, especially as 2027 guidance will be provided with the Q4 report.

Quarterly Backlog Cancellation RateToward the higher end, but within the kind of range we would expect.

Cancellations directly erode backlog and impact future revenue visibility. Monitoring this rate is critical as management highlighted its unpredictability and influence on 2027 guidance, making it a key risk factor for investors.

Net New Business Awards10.6%

This metric is a crucial forward-looking indicator of future revenue and backlog growth. Strong awards signal robust demand for Medpace's services and validate its competitive position, driving investor confidence for the upcoming quarters.

Last reported · 2026-10-21

Key reported metricsRerating thresholdsEarnings results
MetricLast periodWhy it mattersWhat's needed for reratingRerating contextEarnings dateActual reportedHit target?Notes
Net Income per Diluted Share37.1%

A key measure of profitability on a per-share basis, reflecting the company's efficiency and value creation for shareholders. Strong growth indicates effective cost management and higher earnings.

Medpace Holdings, Inc. (MEDP) needs to report Net Income per Diluted Share (EPS) for Q3 2026 exceeding $4.86. This threshold represents a beat of at least 10% over the highest analyst consensus estimate of $4.42 [9, 14], signaling strong operational execution and potential for another upward revision to the full-year 2026 EPS guidance of $17.25-$17.95 [1, 2, 4, 5, 6, 7, 8, 17].

Exceeding EPS expectations by a significant margin demonstrates Medpace's robust operational execution and ability to convert strong bookings into profitable revenue, validating its premium valuation. This would reinforce investor confidence in its growth trajectory and efficiency, driving a positive rerating.

$4.84 (25.4% y/y growth)

No

Medpace reported net income per diluted share of $4.84 for Q3 2026, which was slightly below the rerating trigger of exceeding $4.86. This represents a 25.4% year-over-year increase from $3.86 in the prior year period. Net income growth for the quarter was 23.7%, primarily driven by higher interest income and a lower effective tax rate.

Net Book-to-Bill Ratio28.2%

This ratio is crucial for future revenue visibility. An improvement above 1.0 indicates new business awards are outpacing revenue recognition, signaling healthy backlog growth and future revenue potential.

For Medpace Holdings, Inc. (MEDP) to rerate higher, the Net Book-to-Bill Ratio for Q3 2026 needs to be 1.15x or higher. This would demonstrate sustained and accelerating business momentum, building on the strong 1.13x reported in Q2 2026, which comfortably exceeded analyst expectations of 0.95x to 1.01x. [1, 13] Achieving this level would align with management's expectation of ramping gross bookings in the second half of 2026 and signal continued robust demand in the CRO industry, where a ratio of 1.2x is considered healthy. [10, 12]

A Net Book-to-Bill Ratio of 1.15x or higher is crucial as it signifies that Medpace is securing new business awards at a faster rate than it is converting existing backlog into revenue. This indicates robust demand for its services, healthy backlog growth, and strong future revenue potential, which is essential for justifying its premium valuation and reinforcing the bullish investment thesis. [10]

1.22x

Yes

Medpace reported net new business awards of $873 million in Q3 2026, resulting in a net book-to-bill ratio of 1.22x (calculated as $873 million / $716 million). This exceeded the rerating trigger of 1.15x or higher, demonstrating sustained and accelerating business momentum. Management noted that net new business awards reached an all-time high in the quarter and that the last 12-month closing awards increased by 23.9%.

Total Revenue17.2%

A primary indicator of operational performance and market demand. Investors will monitor if Medpace can sustain its growth trajectory amidst evolving business dynamics and booking trends.

Total Revenue growth of at least 14% year-over-year for Q3 2026, or an upward revision to the full-year 2026 revenue guidance of $2.805 billion to $2.885 billion.

Sustained high revenue growth validates Medpace's strong momentum and ability to convert its robust backlog into recognized revenue. Exceeding guidance reinforces confidence in operational execution and justifies its premium valuation, signaling continued market share gains and strong demand for specialized CRO services.

$716 million (8.5% y/y growth)

No

Medpace's total revenue for Q3 2026 was $716 million, representing an 8.5% year-over-year increase, which missed the rerating trigger of at least 14% year-over-year growth. The company updated its full-year 2026 total revenue guidance to a range of $2.835 billion to $2.855 billion, representing 12% to 12.8% growth over 2025. While the lower end of the growth percentage was raised, the overall guidance range was not a clear upward revision from the previous range of $2.805 billion to $2.885 billion.

Key Questions

Will Medpace's Q4 2026 net new business awards and cancellation rates align with management's optimistic outlook, thereby enabling the company to issue 2027 gui

Will Medpace's Q4 2026 net new business awards and cancellation rates align with management's optimistic outlook, thereby enabling the company to issue 2027 guidance in February that meets or exceeds current analyst consensus expectations?

Question 2

How will the anticipated $20 million in new operating costs from the Cincinnati campus expansion in 2027, combined with the mix of direct fee versus pass-through revenue, impact Medpace's EBITDA margin trajectory and overall profitability in the upcoming year?

Question 3

To what extent will Medpace actively utilize its newly approved $1 billion share repurchase authorization, and how will this capital allocation strategy impact shareholder returns and signal management's confidence in the company's future performance?

Earnings Transcript Summary3 rows
· 2026Q3 Earnings Call
3 Things Management Is Most Focused OnCall Takeaway & TonePrior Quarter'S Y/Y Growth By Segment3 Things Analysts Most Pressed On (And Mgmt Responses)Revenue Segments
3 Things Management Is Most Focused On1. Maintaining a strong business environment and high win rates, leading to record net new business awards: Management highlighted high-quality RFP activity, strong initial award notifications, a good win rate, and net new business awards reaching an all-time high in the quarter. 2. Managing cancellation patterns: Management emphasized the importance of cancellation patterns in Q4 and going into next year, as they significantly influence future revenue expectations. 3. Providing accurate 2027 guidance: Management plans to provide guidance for 2027 at the end of their Q4 reporting in February, stating that they currently see no large disconnect between analyst consensus estimates and their modeling.Call Takeaway & ToneThe overall takeaway from the call is one of cautious optimism. Medpace reported strong Q3 2026 results, with revenue increasing 8.5% year-over-year and net new business awards reaching an all-time high. Management highlighted a robust business environment and an improved win rate. While confident in current performance and 2026 guidance, management expressed caution regarding 2027, emphasizing the unpredictable nature of cancellations as a key factor for future growth and delaying firm 2027 guidance until February. The tone was generally positive regarding current operations and bookings, but measured and forward-looking concerning future growth trajectory due to external factors like cancellations.Prior Quarter'S Y/Y Growth By SegmentTotal revenue increased 17.2% year-over-year in the second quarter of 2026. Segment-specific year-over-year growth rates were not reported for the prior quarter.3 Things Analysts Most Pressed On (And Mgmt Responses)1. Bookings performance and competitive environment: Analysts questioned the source of strong net bookings, the evolving competitive landscape, pricing, and Medpace's differentiation. Management responded that the business environment is strong, with a good win rate and a shift in mix towards traditional oncology, while cancellations were at the higher end but within expectations. 2. 2027 guidance and direct fee vs. pass-through revenue mix: Analysts sought clarification on whether the current consensus for 2027 revenue and EBITDA was accurate and inquired about the direct fee versus pass-through revenue mix, as well as the sustainability of direct fee gross margins. Management reiterated that 2027 consensus looks reasonable and that more color on the mix will be provided in February. They also noted that while Q3 direct fee gross margins were good, they can be lumpy due to accounting, but no significant disruption is expected in Q4. 3. Cancellations: Analysts inquired about the implied lower growth rates for 2027 and asked for more details on the nature and drivers of cancellations in the quarter. Management explained that cancellations are primarily due to product failure and prioritization, not funding issues, and that the decision to delay firm 2027 guidance was due to the evolving view on 2027, with Q4 awards and cancellation patterns being crucial.Revenue SegmentsTotal revenue increased 8.5% year-over-year in the third quarter of 2026. Segment-specific year-over-year growth rates were not reported in the transcript.
· 2026Q2 Earnings Call
3 Things Management Is Most Focused OnCall Takeaway & TonePrior Quarter'S Y/Y Growth By Segment3 Things Analysts Most Pressed On (And Mgmt Responses)Revenue Segments
3 Things Management Is Most Focused On1. Positioning the business for 2027: Management is making good progress in positioning the business for 2027, indicating a forward-looking strategy beyond the current fiscal year. 2. Ramping up gross bookings: Management expects a ramp in gross bookings in the second half of 2026, which they anticipate will translate into a ramp in net bookings. 3. Employee growth and retention: The company is focused on maintaining low employee turnover and expects high single-digit employee growth this year, indicating a stable and growing workforce.Call Takeaway & ToneThe overall takeaway from the call is one of cautious optimism. Management reported a strong business environment in Q2 2026, characterized by record net bookings and a significant improvement in cancellation rates compared to the prior quarter. While revenue growth was solid, there's a clear acknowledgment of a shift in new awards from metabolic back towards oncology, and ongoing discussions around the dynamics of backlog conversion rates and future growth trajectory. Management is focused on ramping gross bookings in the second half of the year and strategically positioning the business for 2027, indicating a forward-looking but measured approach.Prior Quarter'S Y/Y Growth By SegmentTotal revenue increased 26.5% year-over-year in Q1 2026. Segment-specific year-over-year growth rates were not reported for the prior quarter.3 Things Analysts Most Pressed On (And Mgmt Responses)1. Metabolic work concentration and customer concentration: Analysts questioned if metabolic work was driving the concentration of top 5 customers and sought visibility on this trend. Management confirmed that metabolic work has significantly driven top 5 customer growth, but noted a shift with oncology coming back strong in new award notifications and bookings, while new metabolic opportunities have decreased. They expect a return to more historical mix averages over the next year or so. 2. Backlog conversion rate: Analysts pressed on the high backlog conversion rate and whether the metabolic mix was a primary driver. Management clarified that metabolic programs are not the overwhelming driver of the increased conversion rate. Instead, the higher rate is attributed more to their policy of limiting backlog recognition until decision points and the average age of projects. They anticipate the conversion rate will 'tend to drop down some over time'. 3. Cancellations: Analysts inquired about the trend of cancellations, asking if they had improved and their impact on bookings. Management reported that cancellations were 'well behaved' in Q2 2026, representing a substantial drop from Q1, and were more than half the driver of the net bookings increase from the prior quarter. They stated they cannot predict future cancellations but expect gross bookings to ramp up in the second half, which should lead to ramping net bookings if cancellations remain within a 'reasonable range'.Revenue SegmentsTotal revenue increased 17.2% year-over-year in Q2 2026. Segment-specific year-over-year growth rates were not reported in the transcript.
· 2026Q1 Earnings Call
3 Things Management Is Most Focused OnCall Takeaway & TonePrior Quarter'S Y/Y Growth By Segment3 Things Analysts Most Pressed On (And Mgmt Responses)Revenue Segments
3 Things Management Is Most Focused On1. Expanding the pipeline of opportunities and improving the win rate: Management is focused on implementing initiatives to expand their pipeline and improve their win rate to combat higher cancellation rates. 2. Maintaining 2026 revenue guidance: Despite headwinds from cancellations and a sub-1 book-to-bill ratio, management reconfirmed their 2026 guidance, expressing confidence in their current modeling. 3. Investing in AI for future benefits: Management believes AI holds value but expects significant investment over the next two years, with net benefits in efficiency anticipated a few years out.Call Takeaway & ToneThe overall takeaway from the call is one of caution regarding future growth, tempered by management's determined efforts to address current challenges. The tone was mixed, with management acknowledging significant headwinds such as the highest backlog cancellations in over a year and a weak net book-to-bill ratio of 0.88. However, they expressed confidence in maintaining their 2026 revenue guidance and highlighted ongoing initiatives to expand the opportunity pipeline and improve win rates. There's an explicit acknowledgment that sequential growth is a 'real question' for 2027, indicating a more conservative outlook for the longer term if current trends persist.Prior Quarter'S Y/Y Growth By SegmentFor the fourth quarter of 2025, Medpace reported an overall revenue increase of 32.0% year-over-year. No specific segment revenue growth figures were provided for the prior quarter.3 Things Analysts Most Pressed On (And Mgmt Responses)1. Cancellations: Analysts repeatedly questioned the dynamics, drivers, therapeutic areas, and Q2 trends of the elevated cancellations. Management responded that cancellations were due to 'random stuff' like product performance and reprioritizations, not macro-related, with oncology and cardiovascular being the largest therapeutic areas. They stated it was too early to assess Q2 cancellation rates. 2. GLP-1/Metabolic concentration and volatility: Analysts inquired about Medpace's exposure to GLP-1 and metabolic studies and whether this concentration was leading to increased volatility or cancellations. Management clarified that metabolic historically has the lowest cancellation rate among therapeutic areas and that GLP-1 work is 'pretty safe' and 'going fine,' despite potential market saturation impacting new opportunities. 3. Backlog decline and future growth profile: Analysts expressed concern over the declining backlog coverage beyond one year and its implications for future revenue growth. Management acknowledged this as an 'area for concern,' stating that sequential growth in 2027 is a 'real question' and that they need either cancellations to abate or gross awards to increase to achieve a desired growth rate.Revenue SegmentsMedpace reported total revenue of $706.6 million for the first quarter of 2026, representing a year-over-year increase of 26.5% (25.8% on a constant currency basis). No specific revenue segments with year-over-year growth were reported in the transcript.
Transcript Tidbits4 rows
About Expanding Eligible MarketAbout CompetitionAbout The Broader IndustryWhere Things Are HeadedUpdates On ThemeBullish-Leaning Quotes (Short)Bearish-Leaning Quotes (Short)Hiring
About Expanding Eligible MarketThe business environment remains strong, with high-quality RFP activity, strong initial award notifications, and a good win rate. Net new business awards reached an all-time high in the quarter, and the last 12-month closing awards increased by 23.9%. The total dollar value of pending RFPs and opportunities is up nicely, and the total number of opportunities has increased to a very good high. Projects are moving along faster than last year, with clients eager to move forward on opportunities in the current timeframe.About CompetitionMedpace's win rate has been strong, following meaningful adjustments made in processes towards the end of 2025 and early Q1 2026 to address a lower win rate in 2025. The company's large pharma opportunities primarily come from a limited number of providers, often related to biotech clients that were acquired, rather than direct outreach for new large pharma clients. Medpace focuses on the quality of its deliverables and believes the competitive environment has returned to a normalized state, with some 'crazy approaches' from competitors in the past few years having 'died out'.About The Broader IndustryThe therapeutic mix is shifting, with a bit more traditional oncology demand and a little less metabolic demand currently, although there are still many pending opportunities for metabolic work in RFPs. Cancellations are primarily due to product failure, safety signals, or prioritization, rather than funding issues. The company noted that its awards and, to some extent, RFPs have pivoted more back towards oncology.Where Things Are HeadedMedpace expects to provide guidance for 2027 at the end of its Q4 reporting in February, but currently sees no large disconnect between analyst consensus estimates and its own modeling for 2027. Full-year 2026 total revenue is now expected to be between $2.835 billion and $2.855 billion, representing 12% to 12.8% growth over 2025. Full-year 2026 EBITDA is projected to be in the range of $638 million to $652 million, and net income between $514 million and $524 million. Diluted EPS is expected to be $17.97 to $18.32. The company anticipates improving revenue expectations for 2027 month-to-month and expects Q4 to be another record quarter for awards, assuming cancellations remain within range. A new significant expansion in Cincinnati will add about $20 million in operating costs in 2027.Updates On ThemeAIBullish-Leaning Quotes (Short)The business environment remains strong in quarter 26. Net new business awards reached an all time high in the quarter. Our win rate has been strong. Consensus looks reasonable relative to our current modeling. I do not see anything that would significantly disrupt kind of the margin performance in Q4. Things are actually going very well. I think things are moving along faster than last year. Turnover looks very low. I would expect another step up. Things look very good.Bearish-Leaning Quotes (Short)Our cancellations, backlog cancellations this quarter were not something to call out, but also not a help. They were toward the higher end, but within the kind of range we would expect. The implied growth rates for 2027, definitely lower than what Medpace usually does. A large part of that will be kind of what the cancellation profile is in Q4. We see no reason for high cancellations, but these are kind of things that just come out of the blue. Acquisitions are not good for us? No, but it happens all the time.HiringHeadcount grew high single digits sequentially, and the company was able to maintain its margin level, with revenue growing faster than headcount. Turnover rates remain very low, and there are no abnormal pressures on salaries, wages, or benefits, with increases being within expectations.
About Expanding Eligible MarketAbout CompetitionAbout The Broader IndustryWhere Things Are HeadedUpdates On ThemeBullish-Leaning Quotes (Short)Bearish-Leaning Quotes (Short)Hiring
About Expanding Eligible MarketRFPs were up sequentially and year over year, generating high quality opportunities. Initial award notifications remained solid although they declined sequentially from a very strong Q1. The overall environment remains constructive into July, and Medpace is making good progress in positioning the business for 2027. The business environment continued to be strong, and new opportunities look good. The company's pipeline of pre-backlog awarded programs is very strong. RFP numbers have increased substantially year over year and sequentially by a reasonable amount, with quality being more important and consistently good. Medpace is seeing a broader range of clients with recent funding, leading to more opportunities and programs moving forward.About CompetitionMedpace does not see a change in competitive dynamics, stating that the market has gotten stronger. The company acknowledged that its win rate in 2025 was lower than in prior years and that changes were made in late 2025 and early Q1 2026 to address this, which may have influenced the strong win rate in Q1.About The Broader IndustryGrowth over the last year has been significantly driven by metabolic work, particularly from a few large clients. However, oncology has seen a strong comeback in award notifications and bookings in Q2 2026, representing over half of overall bookings and award notifications. Metabolic/cardiometabolic new award notifications have dropped off, indicating a shift back towards more historical averages, with oncology expected to retake its position in the mix over the next year or so. Medpace does not observe a significant shift of Phase 2 trials to China for the programs it is pursuing. Many clients are raising money concurrently with seeking bids for programs.Where Things Are HeadedThe business environment is expected to remain constructive into July, with good progress in positioning for 2027. Medpace anticipates a shift back towards historical therapeutic area mixes, with oncology regaining a larger share over the next year. Gross bookings are expected to scale and ramp up in the second half of the year, which should translate into a ramp in net bookings, assuming cancellations remain within a reasonable range. Full-year 2026 total revenue is now expected in the range of $2.805 billion to $2.885 billion, representing growth of 10.9% to 14% over 2025. EBITDA is projected between $618 million and $642 million, and net income between $494 million and $514 million. Earnings per diluted share are expected to be in the range of $17.25 to $17.95. The reimbursable component of direct costs is expected to decline further in the back half of the year, modeled at 41% to 42% of revenue for Q3 and Q4. Margin expansion is anticipated in the second half due to headcount increases at a slower pace than revenue. The backlog conversion rate is expected to trend downward over time towards historical norms, influenced by the average age of projects and booking characteristics.Updates On ThemeCROs:Bullish-Leaning Quotes (Short)The business environment was strong in Q2 26. Cancellations were well behaved, and supported a record quarter for net bookings. RFPs were up sequentially and year over year, generating high quality opportunities. Overall, the environment remains constructive into July. Net new business awards entering backlog in the second quarter increased 28.2% from the prior year. Oncology represented over half of our overall bookings and our award notifications. Our pipeline of stuff... is very strong. Cancellations were actually in a pretty good range this quarter. We are seeing more opportunities with you know, recent funding and moving forward with the program. I think we are in a good place.Bearish-Leaning Quotes (Short)Initial award notifications remained solid although they declined sequentially from a very strong Q1. Metabolic cardiometabolic has kinda dropped off quite a bit. Cancellations are completely beyond my ability to even yeah. Cancellations are always a wild card. I do not know that it is gonna come down.HiringThe impact of higher reimbursable costs was offset primarily by lower employee related costs in Q2 2026. Headcount growth ticked up slightly, and Medpace believes it is in a good place, substantially helped by low turnover which continued through Q2. The company expects high single-digit growth in employees this year and anticipates this to continue next year. Employee growth has been predominantly in the U.S. and Asia-Pac, with a chunk in India for cost positioning. The biggest growth has been in the U.S., with some repositioning occurring. Headcount increases in the back half of the year are expected to be at a slower pace than revenue, contributing to margin expansion.
About Expanding Eligible MarketAbout CompetitionAbout The Broader IndustryWhere Things Are HeadedUpdates On ThemeBroader Themes EmergingBullish-Leaning Quotes (Short)Bearish-Leaning Quotes (Short)Hiring
About Expanding Eligible MarketMedpace is focused on expanding its pipeline of opportunities and has implemented a number of initiatives to improve its win rate to combat higher cancellation rates. The company believes there are opportunities to expand both the pipeline and the win rate to achieve a desired growth rate.About CompetitionThe market is very competitive, and Medpace aims to improve its win rate, though it is unclear if increased competitiveness is the direct cause of recent trends. The company has not seen a large change in the competitive landscape.About The Broader IndustryBiopharma M&A is generally not good for Medpace, as acquired clients often cut them out of future work, though ongoing projects usually continue. RFP volume was down sequentially and year-over-year. While biotech funding has remained stable, Medpace does not see widespread funding problems or clients merely seeking bids for fundraising purposes. The GLP-1 market, despite becoming saturated and competitive, has not resulted in higher cancellations for Medpace, and metabolic studies historically have the lowest cancellation rate among therapeutic areas. Oncology and cardiovascular were the largest therapeutic areas for cancellations in Q1 2026, which is considered usual.Where Things Are HeadedMedpace's 2026 guidance ranges for revenue, EBITDA, net income, and EPS are unchanged from the prior quarter. However, the company's growth profile in terms of sequential growth for both now and six months from now is a 'real question'. Medpace needs either cancellations to abate or gross awards to increase to restore a desirable growth rate. The company anticipates improving bookings over time. Pass-throughs as a percentage of revenue are expected to end the year lower than the first quarter. Regarding AI, Medpace expects to invest more dollars in trying to achieve future benefits over the next two years than it will gain in efficiency, with net benefits anticipated a few years out.Updates On ThemeCROs:Broader Themes EmergingAI Driven Drug DiscoveryBullish-Leaning Quotes (Short)We continue to view the quality of opportunity flow as good. Initial award notifications and win rate were strong. We feel very good about the range that we have out there, which is why we reconfirmed guidance. We're still hiring. I don't know how you get any more confident than that.Bearish-Leaning Quotes (Short)Quarter 1 of 2026 saw cancellations rise again with backlog cancels reaching their highest point in over a year. Net bookings were below the level of -- seen in Q4, but well above those in Q1 2025 with a net book-to-bill ratio of 0.88. RFPs were down in the quarter sequentially and year-over-year. Acquisitions are not good for us? No, but it happens all the time. Certainly, what we consider a reasonable growth rate is not projected on a sequential basis going forward.HiringMedpace is continuing to hire, which management views as a signal of confidence despite cancellations and softer gross wins. Lower employee-related costs primarily offset the impact of higher reimbursable costs in the first quarter. Improved retention rates are contributing to operating efficiencies, though perhaps at a slower pace.
About Expanding Eligible MarketAbout CompetitionAbout The Broader IndustryWhere Things Are HeadedUpdates On ThemeBroader Themes EmergingBullish-Leaning Quotes (Short)Bearish-Leaning Quotes (Short)Hiring
About Expanding Eligible MarketMedpace is focused on expanding its pipeline of opportunities and has implemented a number of initiatives to improve its win rate to combat higher cancellation rates.About CompetitionThe market is very competitive, and Medpace aims to improve its win rate, though it's unclear if increased competitiveness is the direct cause of recent trends.About The Broader IndustryBiopharma M&A is generally not good for Medpace, as acquired clients often cut them out of future work, though ongoing projects usually continue. While biotech funding has remained stable, RFP weakness was observed, but Medpace does not see widespread funding problems or clients merely seeking bids for fundraising purposes. The GLP-1 market, despite becoming saturated and competitive, has not resulted in higher cancellations for Medpace, and metabolic studies historically have the lowest cancellation rate.Where Things Are HeadedMedpace needs cancellations to abate or gross awards to increase to restore a desirable growth rate, as sequential growth is currently a concern. The company anticipates improving bookings over time. Pass-throughs as a percentage of revenue are expected to end the year lower than the first quarter. AI is expected to require significant investment over the next two years, with actual net benefit on efficiency still a few years out.Updates On ThemeRegardingBroader Themes EmergingAI (Artificial Intelligence)Bullish-Leaning Quotes (Short)We continue to view the quality of opportunity flow as good. Initial award notifications and win rate were strong. We feel very good about the range that we have out there, which is why we reconfirmed guidance. We're still hiring. I don't know how you get any more confident than that. I believe we have very high-quality opportunities, and I haven't seen a deterioration of that.Bearish-Leaning Quotes (Short)Quarter 1 of 2026 saw cancellations rise again with backlog cancels reaching their highest point in over a year. Net bookings were below the level of -- seen in Q4, but well above those in Q1 2025 with a net book-to-bill ratio of 0.88. RFPs were down in the quarter sequentially and year-over-year. Acquisitions are not good for us? No, but it happens all the time. Certainly, what we consider a reasonable growth rate is not projected on a sequential basis going forward.HiringMedpace is continuing to hire, which management views as a signal of confidence. The company has seen improved retention rates, contributing to operating efficiencies.
NotesTable
DateCommentComment TypeComment SentimentLinkPrice Reaction
2026-07-22Medpace reported a strong Q2 2026 with record net bookings (up 28.2%), a 1.13x book-to-bill, and significantly reduced cancellations. Management upgraded 2026 guidance and noted a favorable shift to oncology in new awards, balancing prior metabolic concentration. The stock surged 13.95% (outperforming SPY), indicating strong market approval of the robust performance and positive outlook.Earnings TranscriptPositive+13.95% (vs SPY: +15.08%)
Upcoming Events8 rows
Catalyst IDEstimated TimingEstimated Date StartEstimated Date EndCatalystWhy It MattersTicker Or Theme SpecificTranscript DateSource Type
MEDP_295080d7end the year lower than what we started this year at2026-04-222026-12-31Realization of management's expectation for pass-through revenues to decrease as a percentage of total revenue, driven by the winding down of some metabolic studies.A decrease in the proportion of pass-through revenues, which typically have lower margins, could positively impact the company's overall EBITDA margin and the quality of its revenue.Ticker2026-04-22earnings_transcript
MEDP_e1f9490ea few years out2028-01-012029-12-31Medpace achieving net financial benefits from its investments in Artificial Intelligence (AI) initiatives.While AI is a significant industry trend, management expects that investments in AI will outweigh efficiency gains for at least the next two years, impacting the timeline for any positive financial contribution from AI.Ticker2026-04-22earnings_transcript
MEDP_f4e43f3enot in the near term2026-07-012027-04-22Medpace appoints a new President to succeed Jesse Geiger, who is departing.The appointment of a new President is a key leadership transition that could influence strategic direction, operational execution, and investor confidence, despite management's assurance of a strong team.Ticker2026-04-22earnings_transcript
MEDP_56dbc696second quarter, over the next few quarters2026-04-012027-03-31Trend in Medpace's backlog cancellation rates and net book-to-bill ratio.A sustained high cancellation rate and a book-to-bill ratio below 1.0 would continue to pressure future revenue growth and investor sentiment. An improvement would signal a healthier demand trajectory.Ticker2026-04-23earnings_transcript
MEDP_b929f82bover the next few quarters, immediate term2026-04-012027-03-31Outcome of Medpace's initiatives to expand its pipeline of opportunities and improve its win rate.Successful implementation could combat high cancellation rates and drive an increase in gross awards, which is crucial for restoring a desired growth rate and improving bookings.Ticker2026-04-23earnings_transcript
MEDP_8751ce1e2026 guidance, 20272026-04-232027-12-31Medpace's ability to meet its reconfirmed 2026 financial guidance and the actual sequential revenue growth trajectory in 2027.Achieving 2026 guidance would affirm management's confidence, while the 2027 sequential growth will be a key indicator of the company's long-term growth profile and impact valuation.Ticker2026-04-23earnings_transcript
MEDP_2ffd1934end the year lower than what we started this year at2026-04-232026-12-31Whether pass-through costs as a percentage of revenue decrease by year-end 2026 as projected by management.A reduction in pass-throughs could positively impact EBITDA margins, while a failure to decrease could put pressure on profitability.Ticker2026-04-23earnings_transcript
MEDP_d72516b1next 2 years at least (for investment), a few years out (for net benefit)2026-04-232029-04-23Realization of net efficiency benefits from Medpace's ongoing investments in AI.Significant net benefits from AI could enhance long-term operational efficiency and profitability, while a slower-than-expected realization could impact future cost structures.Ticker2026-04-23earnings_transcript
Prior Earnings Metrics HistoryTable

Prior earnings scorecards